Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

New Phase Research and Development

Neither a doctor nor a teaching hospital

Research payments

$1,460,315

143 payments

Through program year 2025, New Phase Research and Development is reported as receiving $1,460,315 in research payments, across 143 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $102,678 17
2024 Research $136,191 6
2023 Research $27,947 10
2022 Research $568,597 16
2021 Research $79,965 27
2020 Research $348,293 47
2019 Research $196,644 20

Breakdown

Who paid Research payments · program years 2019–2025
  1. Moderna TX, Inc. $552,236 15 payments
  2. AbbVie, Inc. $395,767 69 payments
  3. Ironwood Pharmaceuticals, Inc $196,644 20 payments
  4. Novartis Pharmaceuticals Corporation $184,278 6 payments
  5. AstraZeneca Pharmaceuticals LP $110,079 9 payments
  6. GlaxoSmithKline, LLC. $12,495 6 payments
  7. Pfizer Inc. $6,096 15 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $2,720 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age $506,979 13 payments
  2. McP-103-205 $193,883 14 payments
  3. M16-100 $186,241 23 payments
  4. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $170,395 2 payments
  5. M19-161 $154,239 22 payments
  6. A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma $88,191 5 payments
  7. A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age $45,256 2 payments
  8. Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study $30,221 14 payments
  9. 24-Hour Ambulatory Blood Pressure Monitoring Study in Hypogonadal Men Receiving Testosterone Replacement Therapy $25,066 10 payments
  10. AstraZeneca is developing mAbs to the SARS CoV 2 spike protein. The SARS CoV 2 spike protein contains the virus RBD which enables the virus to bind to receptors on human cells. By targeting this region of the virus spike protein antibodies can block the virus attachment to human cells and therefore is expected to block infection. Amino acid substitutions have been introduced into the antibodies to both extend their half lives which should prolong their potential prophylactic benefit and decrease $21,889 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record